Tumor Lysis Syndrome News and Research

RSS
Proteolix announces positive data for carfilzomib in patients with relapsed and refractory multiple myeloma

Proteolix announces positive data for carfilzomib in patients with relapsed and refractory multiple myeloma

Rituxan in combination with chemo improves survival in chronic lymphocytic leukemia

Rituxan in combination with chemo improves survival in chronic lymphocytic leukemia

Trial shows Elitek significantly reduces plasma uric acid levels versus Allopurinol in adults with hematologic cancers at risk for tumor Lysis syndrome

Trial shows Elitek significantly reduces plasma uric acid levels versus Allopurinol in adults with hematologic cancers at risk for tumor Lysis syndrome

Rituximab reduces disease activity in multiple sclerosis

Rituximab reduces disease activity in multiple sclerosis

Results from study of Rituxan in rheumatoid arthritis show promise

Results from study of Rituxan in rheumatoid arthritis show promise

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.